PLK4 Inhibitors Selective Kinase Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for selective kinase inhibitors for Polo-like kinase 4 (PLK4) to prevent centriole overduplication, which can lead to cancer, as existing methods are not specific enough and may affect other kinases like Aurora kinases.
Innovation Solution
Development of specific compounds that inhibit PLK4 by binding to its kinase domain, thereby preventing centriole overduplication and cancer progression, including the use of centrinone, which selectively targets PLK4 and depletes centrioles from cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing kinase inhibitors are used to target PLK4, then centriole overduplication can be inhibited, but other kinases like Aurora kinases are also affected leading to lack of selectivity
Solution Approach 1:
The patent introduces a specific substituent at the C5 position of the pyrimidine ring (such as -CH2OCH3, -CH2OH, or -CF3 groups) that creates local chemical characteristics selective for PLK4 binding. This local modification allows the inhibitor to distinguish PLK4 from other kinases like Aurora A and B, achieving selective inhibition without affecting off-target kinases.
Solution Approach 2:
The patent systematically varies chemical parameters of the pyrimidine core structure, including substituents at C2, C5, and N1 positions, to optimize binding affinity and selectivity for PLK4. By changing parameters such as the type of substituent group (ether, hydroxyl, fluoromethyl) and their positions, the invention achieves high selectivity for PLK4 while maintaining potent inhibitory activity.
2Reliability
If selective PLK4 inhibitors are developed to avoid affecting other kinases, then therapeutic specificity is improved, but compound design and synthesis complexity increases
Solution Approach 1:
The patent divides the inhibitor molecule into distinct functional segments: a pyrimidine core structure, specific substituents at defined positions (C2, C5, N1), and optional additional groups. This segmentation allows systematic optimization of each segment's contribution to selectivity and activity, simplifying the design process despite the overall molecular complexity required for selective PLK4 inhibition.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively inhibit PLK4 kinase activity, leading to reversible depletion of centrioles, preventing cancer progression by targeting PLK4 specifically without affecting other kinases, thus offering a therapeutic approach for cancers overexpressing PLK4.
Implementation Method 1
The compounds effectively inhibit PLK4 kinase activity, leading to reversible depletion of centrioles
Implementation Method 2
centrinone, which selectively targets PLK4 and depletes centrioles from cells
Data Source
Figure 1A~1C
Figure 1D
Figure 1E
AI summary
Provided herein, inter alia, are compounds and methods for inhibiting PLK4 and for treating cancer in a subject in need thereof.